nach oben

Archives of Virology

Erschienen in:

01.05.2024 | Brief Report

Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes

verfasst von: Soma Das, Padmanava Behera, Dipeshwari J Shewale, Janhavi Bodele, Saumitra Das, Anjali A Karande

Erschienen in: Archives of Virology | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Previously, we reported a neutralizing monoclonal antibody, A8A11, raised against a novel conserved epitope within the hepatitis C virus (HCV) E2 protein, that could significantly reduce HCV replication. Here, we report the nucleotide sequence of A8A11 and demonstrate the efficacy of a single-chain variable fragment (scFv) protein that mimics the antibody, inhibits the binding of an HCV virus-like particle to hepatocytes, and reduces viral RNA replication in a cell culture system. More importantly, scFv A8A11 was found to effectively restrict the increase of viral RNA levels in the serum of HCV-infected chimeric mice harbouring human hepatocytes. These results suggest a promising approach to neutralizing-antibody-based therapeutic interventions against HCV infection.

Guidelines on hepatitis B and C testing (2017) Geneva: World Health Organization; (http://apps.who.int/iris/bitstream/10665/254621/1/9789241549981, accessed 17 July 2018).

Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436(7053):946–952. https://doi.org/10.1038/nature04079CrossRefPubMed

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339(21):1485–1492. https://doi.org/10.1056/NEJM199811193392101CrossRefPubMed

Christoph Sarrazin C, Hézode S, Zeuzem J-M, Pawlotsky (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56 (Suppl 188–100. https://doi.org/10.1016/S0168-8278(12)60010-5

Welsch C, Jesudian A, Zeuzem S, Jacobson I (2012) New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61(Suppl 1):i36–46. https://doi.org/10.1136/gutjnl-2012-302144CrossRefPubMed

Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13:34–41. https://doi.org/10.1111/j.1365-2893.2005.00651.xCrossRefPubMed

Kuiken C, Simmonds P (2009) Nomenclature and numbering of the hepatitis C virus. Methods Mol Biol 510:33–53. https://doi.org/10.1007/978-1-59745-394-3_4CrossRefPubMed

Weisser NE, Hall JC (2009) Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv 27:502–520. https://doi.org/10.1016/j.biotechadv.2009.04.004CrossRefPubMed

Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M (2012) 2012 scFv Antibody: Principles and Clinical Application. J Immunol Res vol Article ID 980250:15. https://doi.org/10.1155/2012/980250CrossRef

10.

Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M; (1988) Single-chain antigen-binding proteins. Science 242:423–426. https://doi.org/10.1126/science.3140379CrossRefPubMed

11.

Sapats SI, Heine HG, Trinidad L, Gould GJ, Foord AJ, Doolan SG, Prowse S, Ignjatovic J (2003) Generation of chicken single chain antibody variable fragments (scFv) that differentiate and neutralize infectious bursal disease virus (IBDV). Arch Virol 148:497–515. https://doi.org/10.1007/s00705-002-0931-2CrossRefPubMed

12.

Li T-W, Cheng S-F, Tseng Y-T, Yang Y-C, Liu W-C, Wang S-C, Chou M-J, Lin Y-J, Wang Y, Hsiao P-W, Wu S-C Ding-Kwo Chang 2016 Development of single-chain variable fragments (scFv) against influenza virus targeting hemagglutinin subunit 2 (HA2). Arch Virol, 161, 19–31. https://doi.org/10.1007/s00705-015-2625-6

13.

Li B, Ye J, Lin Y, Wang M, Jia R (2014) Jianguo ZhuSelection and characterization of single-chain recombinant antibodies against phosphoprotein of Newcastle disease virus. Biologicals, 42, 285–289. https://doi.org/10.1016/j.biologicals.2014.05.006

14.

Das S, Mullick R, Kumar A, Tandon H, Bose M, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Srinivasan N, Das S, Shaila MS, Karande AA 2017 Identification of a novel epitope in the C-terminus of HCV-E2 protein that induces potent and cross-reactive neutralizing antibodies. J Gen Virol. 98(5): 962–976. https://doi.org/10.1099/jgv.0.000735

15.

Das S, Shetty RK, Kumar A, Shridharan RN, Tatineni R, Chi G, Mukherjee A, Das S, Subbarao SM, Karande AA 2013 Monoclonal Antibodies against Hepatitis C Genotype 3a Virus Like Particle Inhibit Virus Entry in Cell Culture System. PLoS ONE, 8:e53619 https://doi.org/10.1371/journal.pone.0053619

16.

Kanyarat Thueng-in Jeeraphong Thanongsaksrikul, Surasak Jittavisutthikul, Watee Seesuay, Monrat Chulanetra, Yuwaporn Sakolvaree, Potjanee Srimanote, Wanpen Chaicumpa 2014 Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase, mAbs, 6:5, 1327–1339 https://doi.org/10.4161/mabs.29978

17.

Kumar A, Das S, Mullick R, Lahiri P, Tatineni R, Goswami D, Bhat P, Torresi J, Gowans EJ, Karande AA, Das S 2016 Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy. Vaccine 34(8):1115–1125 https://doi.org/10.1016/j.vaccine.2015.11.061

18.

Reddy U, Mullick R, Kumar A, Sharma G, Bag P, Laha Roy C, Sudha G, Tandon H, Dave P, Shukla A, Srinivasan P, Nandhitha M, Srinivasan, Das S 2018 A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage. Antiviral Res 150: 47–59. https://doi.org/10.1016/j.antiviral.2017.12.004

19.

Kabat; T EA, Wu T (1991) Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 147(5):1709–1719. https://doi.org/10.4049/jimmunol.147.5.1709CrossRef

Titel: Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes
verfasst von: Soma Das
Padmanava Behera
Dipeshwari J Shewale
Janhavi Bodele
Saumitra Das
Anjali A Karande
Publikationsdatum: 01.05.2024
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 5/2024
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-024-06024-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Serum/glucocorticoid-regulated kinase 1 contributes to the proliferation of varicella-zoster virus and induction of cyclin B1 expression

Genomic characterization of human respiratory syncytial virus circulating in Islamabad, Pakistan, during an outbreak in 2022-2023

Rapid and sensitive visual detection of avian leukosis virus by reverse transcription loop-mediated isothermal amplification combined with a lateral flow immunochromatographic strip assay

Genome analysis and classification of Xanthomonas bacteriophage AhaSv, a new member of the genus Salvovirus

Development of a novel sensitive single-tube nested PCR assay for the detection of African swine fever virus

Biological characterization and complete genome analysis of the newly isolated Serratia liquefaciens phage vB_SlqS_ZDD2